The Cerament G implantable device/drug combination provides a pathway for a single-stage approach to bone infections for those susceptible to bone fractures and foot ulcers.
Surgeons and hospitals can receive up to 65 percent reimbursement when using Cerament G, according to the email. Reimbursement is only applicable to Medicare patients.
Treatment cost savings are due to the product’s effectiveness, which reduces the need for follow-up procedures and post-surgical complications.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.